Serum Institute begins Covishield’s clinical trial in India

Serum institute gets promising results for 3 volunteers on antibody test reports of COVID-19 vaccine 

Serum Institute has been working on a COVID-19 vaccine in India called ‘Covishield’. The human trials for the vaccine developed by the University of Oxford started on Tuesday. The first patients were screened by Bharati Vidyapeeth Deemed University (BVDU) Medical College and Hospital in Pune.

Expect COVID-19 Vaccine By End Of 2020: Serum Institute Of India

Medical Director of Bharti Vidyapeeth’s Medical Hospital informed ANI, “Five volunteers were tested for RT-PCR & antibodies, out of whom reports of three showed they have antibodies, hence the vaccine was administered to two.”

A participant is only eligible for screening and testing after getting the approval from the ethics committee of the hospital. Currently, about 7 hospitals including the BVDU have received the approval from the ethics committee.

Serum Institute is one of the third firms that is conducting human trials of the COVID-19 vaccine in india. The other two companies, Bharat Biotech (for Covaxin) and Zydus Cadila (for ZyCoV-D) started their phase I and II trials in July.

Sanjay Lalwani, principal investigator at BVDU informed yesterday that the hospital seeks to have about 300-350 participants as part of the trials.

Total
2
Shares
Related Posts
Total
2
Share